Martin Hunt

Martin Hunt

Non-Executive Chairman

Martin has over 30 years' experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Martin is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board.


Stuart Ashman

Chief Executive

Stuart has over 20 years' experience in the medical device and life science sectors and most recently was CEO of Onbone Oy ("Onbone"), a Finnish private equity-backed medical device company. In this role, he successfully established a global sales force and distribution network and led the growth of a multi-million pound business. Prior to Onbone, Mr Ashman was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer, and before then, was President/CEO of TI Group, a UK-based medical/engineering company. Stuart also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.


Dr Catherine O'Neill

Dr Cath O'Neill

Chief Scientific Officer

Cath is an accomplished biologist and a leader in human-bacterial interactions. Cath previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Cath has worked as an advisor for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto to new product concepts in partnership with global corporations. Cath is a biochemist by training and has previously led research teams as a senior lecturer at the University of Manchester.


Doug Quinn, Chief Financial Officer

Doug Quinn

Chief Financial Officer

Doug has spent the last 15 years involved in start-up and early stage businesses helping to manage them through subsequent levels of growth and secure the requisite funding. Doug has operational experience both within finance and across other business functions as well as considerable corporate finance experience, including in public markets. He was previously CFO at AIM listed Arthro Kinetics Plc and is currently CFO with regenerative medicine company Videregen and prior to joining Skin Biotherapeutics was CFO with University of Manchester spinout Gelexir Healthcare.


Dr Cathy Prescott

Non-Executive Director

Cathy has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., non-executive Director Videregen Ltd., chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member Babraham Institute and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme 'Cellular Therapies from bench to market' and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University).